• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Michele McCourt Discusses Impact of High Costs for Patients With Cancer

Video

High costs in cancer care not only affects treatment outcomes for patients, but also their overall quality of life, explained Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation.

High costs in cancer care not only affects treatment outcomes for patients, but also their overall quality of life, explained Michele McCourt, senior director of the CancerCare Co-Payment Assistance Foundation.

Transcript

What is the impact of high costs on access to care for patients with cancer?

Patients with cancer, we actually do a survey. Patients with cancer, the high costs, it’s referred to as financial toxicity. It affects their overall quality of life in a negative way. It impacts their quality of life and they’re having to make tough choices. So, patients will either walk away from treatment, they will try and take their medications spread out over time so they aren’t taking their medications properly so they aren’t adhering to the way they are supposed to take their medication and it’s becoming ineffective. It really affects their quality of life.

The other thing is they might be taking because they don’t want to take the medication that really works best for them, they might choose a medication that has different treatment side effects. So, making those tough choices just to save as much money as they can, it negatively impacts their life.

Related Videos
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Screenshot of Susan Wescott, RPh, MBA
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Screenshot of an interview with Adam Colborn, JD
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.